The rest of 2019 is looking busy for Hansa Biopharma AB and the biotech has divested its equity holding in fellow Swedish group Genovis AB to help fund its pipeline of therapies for rare diseases.
The Lund-headquartered group, which specializes in immunomodulatory enzyme technology for rare immunoglobulin G (IgG)-mediated diseases, has sold its entire stake...








